Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3 domain-containing protein 19 (SH3D19) is a protein encoded by the SH3D19 gene in humans and contains multiple Src homology 3 (SH3) domains, which are modular domains critical for mediating protein–protein interactions via binding to proline-rich motifs on target proteins[2][3][7]. SH3D19 interacts with proteins such as EBP and members of the ADAM protein family, suggesting a role in modulating the signaling pathways associated with EGFR-ligand shedding[2][5][7]. It may also participate in suppression of Ras-mediated cellular transformation, regulation of cell morphology, and cytoskeletal organization, and is implicated in various vesicle trafficking processes[2][5]. There are no well-characterized drug interactions, biomarker use, or known therapeutic applications for this protein. Its relevance to disease appears limited to some reported associations, such as selective IgG deficiency, but it is not considered a canonical therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SH3 domain-containing protein 19 (SH3D19).